Plus Therapeutics Profit Margin

The latest profit margin for PSTV is 485.79% as of March 2026. That compares with -1159.88% in the prior-year period — up 141.9% year over year. That is above the Healthcare sector average of 15.29%. Investors often review this figure alongside Plus Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PSTV's profit margin moved from -1159.88% to 485.79% — a 141.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Plus Therapeutics's valuation or profitability profile.

Against Healthcare companies, PSTV currently prints 485.79% for profit margin, while the sector average sits near 15.29%. That is roughly 3076.6% above the sector mean. Large gaps often invite a closer look at Plus Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Plus Therapeutics converts resources into returns. At 485.79%, PSTV may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1159.88% in the prior-year period — up 141.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PSTV's profit margin (485.79%), review year-over-year change from -1159.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.